"startup competition" "healthcare"

Sixth Wave Innovations Inc. and Mining and Process Solutions Complete Phase 1 "Green Lixiviant" Testing for Gold Mining with Outstanding Results

Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: SIXWF) (FSE: AHUH) (the "Company" or "Sixth Wave") is pleased to report results that demonstrate the extraction of gold at high capacity with lower reagent costs. These results were achieved during the successful completion of Phase 1 of the "Green Alternatives for Gold Leaching and Recovery" initiative (the "Green Initative") undertaken with the Centre Technologique des Résidus Industriels ("CTRI") and Australian company Mining and Process Solutions ("MPS"). The Company has worked closely with MPS and CTRI for the past 7 months to test the efficacy of Sixth Wave's IXOS® molecularly imprinted polymer for gold extraction in conjunction with the MPS GlyCat™ process.

IXOS® has previously been proven effective in the extraction of gold from cyanide leach solutions and the completion of Phase 1 of the Green Initiative has demonstrated the ability of IXOS® to extract gold from the pregnant leach solution generated by MPS' GlyCat™technology. IXOS® has proven superior to traditional activated carbon technology by demonstrating a higher selectivity for gold relative to other gangue materials, resulting in a higher gold capture than activated carbon.

A major Canadian mining company participating in the research project provided the requisite ore samples. Phase 1 tests used IXOS®with the GlyCat™technology to determine Glycat's characteristics and capabilities while confirming IXOS® can adsorb gold from solution with typically an order of magnitude lower cyanide usage.

IXOS® used in combination with the GlyCat™process achieved outstanding gold recovery and the test results demonstrated a much lower reagent cost. Additionally, the use of IXOS® beads for adsorption during the stirred-batch-reactor testing showed excellent adsorption performance in combination with the glycine catalysed leaching process; achieving recoveries that were on par or slightly higher than recoveries using a more traditional cyanide-leach process.

With the successful completion of Phase 1, Phase 2 testing will focus on meeting Canadian ecotoxicity guidelines. Upon successful completion of Phase 2, Phase 3 testing will involve the design of a process circuit that validates the performance of IXOS® and GlyCat™ in a full-scale pilot plant at an operating gold mine in Canada. MPS has conducted environmental impact studies for the deployment of the GlyCat Process in Australia. The overall project goal is to develop an environmentally friendly flow sheet for the gold mining industry.

"Our collaboration with MPS and CTRI is a major focal point of our mining division activities," said Sherman McGill, Executive Vice President for Sixth Wave. "We are keenly aware of the need for environmental innovation and safeguards. Phase 1 test results indicate that we can successfully leverage our technology with the benefits of MPS'' GlyCat™ Process. The CTRI project is an important initiative for Sixth Wave and our IXOS® high performance gold extraction products. It is clear that the mining industry is aggressively seeking new and innovative approaches to leach and recover gold as a replacement, in whole or in part, for conventional processes. We believe gold mining companies will have significant interest in learning more about our results and how the technology may benefit their operations."

"We are very pleased to be in collaboration with Sixth Wave", states Mr. Ivor Bryan, Managing Director of MPS. "Our respective technological approaches can bring tremendous value to prospective customers by significantly cutting cyanide usage along with the associated costs and environmental impact."

About IXOS® Technology

The foundation of Sixth Wave's products for the resource sector is its IXOS® advanced extraction media developed using Molecularly Imprinted Polymers ("MIPs"). MIPs contain specifically engineered cavities designed to target and capture molecules of interest, based on molecular geometry and ionic charge. IXOS® media have the ability to attract target molecules to the exclusion of other undesirable elements.

For gold applications, the IXOS® platform is capable of selectively targeting gold while rejecting contaminants such copper, mercury, and other non-target elements potentially contained in a gold-bearing cyanide leach solution. Non-selectivity is a comparative disadvantage of activated carbon, which tends to recover a variety of undesirable ancillary metals that affect gold process economics and purity.

Test results for extraction of gold from cyanide leach solutions have demonstrated the ability to capture elevated quantities of gold as compared to traditional activated carbon. MIPs nanotechnology can be applied to other target elements in addition to gold, including both inorganic and organic elements that require removal from solution.

About Sixth Wave

Sixth Wave is a nanotechnology company focused on extraction and detection of target substances at the molecular level using its patented technologies in the highly specialized field of molecularly imprinted polymers. Sixth Wave has commercialized IXOS®, a line of extraction polymers for the gold mining industry.

For more information about Sixth Wave, please visit www.sixthwave.com

About Mining and Process Solutions (MPS)

MPS holds exclusive global rights to the Glycine Leaching process developed by Curtin University. The company was formed in 2014 as a privately owned and funded company headquartered in Perth, Australia. MPS has 5 international patents granted and pending for Glycine leaching. MPS is developing a number of leaching processes with its GlyCat™process currently available to the market. Two commercial operations in Africa are using the technology to retreat copper/gold tailings that would otherwise be an environmental waste liability. MPS was selected as the 2021 winner of the cleantech category in the global Extreme Technology Challenge - the competition consisted of 3700 startups and is the world's largest startup competition. MPS was also the overall winner of the 2019 Western Australia Innovator of the Year Award and winner of the 2017 Australian Technologies Competition - Mining Sector.

For more information about MPS, please visit www.mpsinnovation.com.au

ON BEHALF OF THE BOARD OF DIRECTORS
"Jon Gluckman"
Jonathan Gluckman, Ph.D., President & CEO

For information, please contact the Company:
Phone: (801) 582-0559
E-mail: info@sixthwave.com

Cautionary Notes

This press release includes certain statements that may be deemed "forward-looking statements" including statements regarding IXOS® system scale-up, performance and commencement of full-scale production. All statements in this release, other than statements of historical facts, that address future events or developments that the Company expects, are forward looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual events or developments may differ materially from those in forward-looking statements. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, including the risks that IXOS® system performance may not be maintained at production level, that anticipated cost savings and performance levels relative to competing technologies may not be realized, that other technologies with better performance or costs may be developed by competitors, and other risks detailed in the Company's filing statement available at www.sedar.com, which may cause the Company's actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/95851

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Tryptamine Therapeutics Limited

Successful Maiden Dosing of TRP-8803 (IV-Infused Psilocin) Completed in Global First

Tryptamine Therapeutics Limited (‘Tryp’ or the ‘Company’) (ASX: TYP), a clinical-stage biotechnology company focused on the development of an innovative and scalable intravenous-infused psilocin formulation which may be used in conjunction with psychotherapy to address significant unmet medical needs, is pleased to advise that it has successfully and safely completed the world’s first participant dosing using TRP-8803 (IV-infused psilocin) in a patient in Adelaide, South Australia.

Keep reading...Show less
Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension  of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies

Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies

  • Bexicaserin achieved an overall median seizure reduction of 56.1% in countable motor seizures over an approximate 6-month treatment period; participants randomized to the PACIFIC placebo group achieved a median seizure reduction of 57.3%
  • Favorable safety and tolerability results observed
  • 100% of participants who completed the PACIFIC Study entered the OLE
  • End of Phase 2 Meeting scheduled for this summer

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive interim results from its ongoing 52-week open-label extension of the PACIFIC Study evaluating bexicaserin (LP352) in participants ages 12-65 years old with Developmental and Epileptic Encephalopathies.

"We are thrilled to see a sustained, durable response in seizure reduction and a favorable safety and tolerability profile across a broad range of DEE patients. Additionally, we saw compelling seizure reduction in the PACIFIC placebo patients who transitioned to bexicaserin in the OLE. These data provide further support to bexicaserin's potential to offer a highly differentiated and best-in-class profile," stated Dr. Randall Kaye, Longboard's Chief Medical Officer.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver  in Milan

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver in Milan

SZN-043 is a novel biotherapeutic shown to potentiate Wnt signaling and induce proliferation of hepatocytes in preclinical models

Treatment with SZN-043 in the Phase 1a trial was safe and well tolerated in healthy volunteers and patients with a history of liver cirrhosis

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Annexon Announces Pricing of $125 Million Underwritten Public Offering

Annexon Announces Pricing of $125 Million Underwritten Public Offering

Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the pricing of its previously announced underwritten public offering of 13,001,120 shares of its common stock at a price to the public of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 7,000,000 shares of common stock at a purchase price of $6.249 per share, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (INKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 12, 2024, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET.

To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/INKT2024 and enter the 16-digit control number found in their proxy materials. Guests may also access the meeting in listen-only mode. No control number is required for guests.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024

97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study

EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barrier to Resistance

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×